Nelivaptan
From Wikipedia, the free encyclopedia
(Redirected from SSR149415)
| Systematic (IUPAC) name | |
|---|---|
| (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Identifiers | |
| CAS number | 439687-69-1 |
| ATC code | None |
| PubChem | CID 9895468 |
| ChemSpider | 8071134 |
| UNII | 3TY57MQ4OA |
| ChEMBL | CHEMBL582857 |
| Chemical data | |
| Formula | C30H32ClN3O8S |
| Mol. mass | 630.11 g/mol |
|
|
| |
|
Nelivaptan (INN[1]), codenamed SSR-149,415, is a selective and orally active non-peptide vasopressin receptor antagonist selective for the V1b subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]
[edit] References
- ^ World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98". WHO Drug Information 21 (4): 341. http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf.
- ^ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. doi:10.1073/pnas.092012099. PMC 122955. PMID 11959912. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=122955.
- ^ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS drug reviews 11 (1): 53–68. doi:10.1111/j.1527-3458.2005.tb00035.x. PMID 15867952.
- ^ "Second-quarter 2008 results". Press Release. Sanofi-Aventis. 2008-07-31. http://en.sanofi-aventis.com/binaries/20080731_results2008_Q2_CP_EN_tcm28-20271.pdf. Retrieved 2009-06-10. "It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist)."
[edit] External links
|
||||||||||||||||||||||||||||||||||
| This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |